Current developments of SELEX technologies and prospects in the aptamer selection with clinical applications

IF 3.5 Q3 Biochemistry, Genetics and Molecular Biology
Danny Jair Chinchilla-Cárdenas , Juan Sebastian Cruz-Méndez , Julieth Michel Petano-Duque , Ramón Ovidio García , Lyda R Castro , María Jesús Lobo-Castañón , Giovanni Orlando Cancino-Escalante
{"title":"Current developments of SELEX technologies and prospects in the aptamer selection with clinical applications","authors":"Danny Jair Chinchilla-Cárdenas ,&nbsp;Juan Sebastian Cruz-Méndez ,&nbsp;Julieth Michel Petano-Duque ,&nbsp;Ramón Ovidio García ,&nbsp;Lyda R Castro ,&nbsp;María Jesús Lobo-Castañón ,&nbsp;Giovanni Orlando Cancino-Escalante","doi":"10.1016/j.jgeb.2024.100400","DOIUrl":null,"url":null,"abstract":"<div><p>Aptamers are single-stranded oligonucleotide sequences capable of binding to specific ligands with high affinity. In this manner, they are like antibodies but have advantages such as lower manufacturing costs, lower immunogenicity, fewer batch-to-batch differences, a longer shelf life, high tolerance to different molecular milieus, and a greater number of potential targets. Due to their special features, they have been used in drug delivery, biosensor technology, therapy, and diagnostics. The methodology that allowed its production was the “Systematic Evolution of Ligands by Exponential enrichment” (SELEX). Unfortunately, the traditional protocol is time-consuming and laborious. Therefore, numerous variants with considerable optimization steps have been developed, nonetheless, there are still challenges to achieving real applications in the clinical field. Among them, are control of <em>in vivo</em> activities, fast renal filtration, degradation by nucleases and toxicity testing. This review focuses on current technologies based on SELEX, the critical factors for successful aptamer selection, and its upcoming biomedical and biotechnological applications.</p></div>","PeriodicalId":53463,"journal":{"name":"Journal of Genetic Engineering and Biotechnology","volume":"22 3","pages":"Article 100400"},"PeriodicalIF":3.5000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1687157X24001033/pdfft?md5=8886b18a015cf67f98620836b74bfa7b&pid=1-s2.0-S1687157X24001033-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Genetic Engineering and Biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1687157X24001033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Aptamers are single-stranded oligonucleotide sequences capable of binding to specific ligands with high affinity. In this manner, they are like antibodies but have advantages such as lower manufacturing costs, lower immunogenicity, fewer batch-to-batch differences, a longer shelf life, high tolerance to different molecular milieus, and a greater number of potential targets. Due to their special features, they have been used in drug delivery, biosensor technology, therapy, and diagnostics. The methodology that allowed its production was the “Systematic Evolution of Ligands by Exponential enrichment” (SELEX). Unfortunately, the traditional protocol is time-consuming and laborious. Therefore, numerous variants with considerable optimization steps have been developed, nonetheless, there are still challenges to achieving real applications in the clinical field. Among them, are control of in vivo activities, fast renal filtration, degradation by nucleases and toxicity testing. This review focuses on current technologies based on SELEX, the critical factors for successful aptamer selection, and its upcoming biomedical and biotechnological applications.

SELEX 技术的发展现状和临床应用中选择适配体的前景
Aptamers 是单链寡核苷酸序列,能够与特定配体高亲和力结合。因此,它们与抗体类似,但具有制造成本低、免疫原性低、批次间差异小、保质期长、对不同分子环境的耐受性高以及潜在靶点多等优点。由于其特殊性,它们已被用于药物输送、生物传感器技术、治疗和诊断。其生产方法是 "配体指数富集系统进化"(SELEX)。遗憾的是,传统方案费时费力。因此,人们开发了许多具有大量优化步骤的变体,但要在临床领域实现真正的应用仍面临挑战。其中包括体内活性控制、快速肾过滤、核酸酶降解和毒性测试。本综述将重点介绍基于 SELEX 的现有技术、成功选择适配体的关键因素及其即将到来的生物医学和生物技术应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Genetic Engineering and Biotechnology
Journal of Genetic Engineering and Biotechnology Biochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
5.70
自引率
5.70%
发文量
159
审稿时长
16 weeks
期刊介绍: Journal of genetic engineering and biotechnology is devoted to rapid publication of full-length research papers that leads to significant contribution in advancing knowledge in genetic engineering and biotechnology and provide novel perspectives in this research area. JGEB includes all major themes related to genetic engineering and recombinant DNA. The area of interest of JGEB includes but not restricted to: •Plant genetics •Animal genetics •Bacterial enzymes •Agricultural Biotechnology, •Biochemistry, •Biophysics, •Bioinformatics, •Environmental Biotechnology, •Industrial Biotechnology, •Microbial biotechnology, •Medical Biotechnology, •Bioenergy, Biosafety, •Biosecurity, •Bioethics, •GMOS, •Genomic, •Proteomic JGEB accepts
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信